Home Biosimilar Antibodies Others Others Anti-MICA (CLN-619)
For research use only. Not for use in humans.

Anti-MICA (CLN-619)

Synonyms: MIC-A,PERB11.1

Anti-MICA (CLN-619) is a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the natural-killer group 2, member D receptor protein (NKG2D or KLRK1) ligands MHC class I polypeptide-related sequence A (MICA) and B (MICB), with potential immunostimulating and antineoplastic activities. MW: 146.06 kD.

Anti-MICA (CLN-619)

Quality Control

Batch: A275301 Purity: 99% Protein concentration: 6.087mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Anti-MICA (CLN-619) is a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the natural-killer group 2, member D receptor protein (NKG2D or KLRK1) ligands MHC class I polypeptide-related sequence A (MICA) and B (MICB), with potential immunostimulating and antineoplastic activities. MW: 146.06 kD.
References

Product Details

Molecular Weight 146.06
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06381141 ACTIVE_NOT_RECRUITING Drug: CLN-619 Multiple Myeloma Cullinan Therapeutics Inc. 2024-09-03 PHASE1
NCT06328673 ACTIVE_NOT_RECRUITING Drug: DM919|Drug: Pembrolizumab Advanced Solid Tumor D2M Biotherapeutics Inc. 2024-04-09 PHASE1
NCT05117476 ACTIVE_NOT_RECRUITING Drug: CLN-619|Drug: Pembrolizumab|Drug: Paclitaxel|Drug: Car Advanced Solid Tumor; NSCLC Cullinan Therapeutics Inc. 2021-10-29 PHASE1

(data from https://clinicaltrials.gov, updated on 2025-09-18)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.